Tag results:
atopic dermatitis
Dermal Cell News
VYNE Therapeutics Announces Phase Ib Data for FMX114 from Phase Ib/IIa Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
[VYNE Therapeutics, Inc.] VYNE Therapeutics, Inc. announced that it has completed the Phase Ib portion of a Phase Ib/IIa clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis
Dermal Cell News
ASLAN Pharmaceuticals Initiates Phase IIb Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis
[ASLAN Pharmaceuticals] ASLAN Pharmaceuticals announced that it has screened the first patient in its Phase IIb dose-ranging clinical study of eblasakimab in adults with moderate-to-severe atopic dermatitis.
Dermal Cell News
Expression Pattern and Immunoregulatory Roles of Galectin-1 and Galectin-3 in Atopic Dermatitis and Psoriasis
[Inflammation] Researchers evaluated galectin (Gal)-1 and Gal-3 levels, which are beta-galactoside-binding proteins with immunomodulatory functions and examined their effects on human keratinocytes stimulated with either interleukin (IL)-4 or IL-17A.
Dermal Cell News
US FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis
[Pfizer, Inc.] Pfizer, Inc. announced that the US FDA approved CIBINQO® (abrocitinib), an oral, once-daily, Janus kinase 1 inhibitor, for the treatment of adults living with refractory, moderate-to-severe atopic dermatitis.
Dermal Cell News
Good Practice Intervention for Clinical Assessment and Diagnosis of Atopic Dermatitis: Findings from the Atopic Dermatitis Quality of Care Initiative
[Dermatologic Therapy] The best clinical practices used by leading atopic dermatitis (AD) centers included the use of validated diagnostic criteria, established AD scoring tools including patient-reported outcome measures and electronic health records, the formation of multidisciplinary teams, and improved communication between health care providers and patients.
Dermal Cell News
European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis
[Pfizer, Inc.] Pfizer, Inc. announced that the European Commission has approved the 100 mg and 200 mg doses of Cibinqo®, an oral, once-daily, Janus kinase 1 inhibitor, for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.